Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258).
Kim, E., et al. Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. J Clin Oncol 38: 2020 (suppl; abstr e17506). DOI:10.1200/JCO.2020.38.15_suppl.e17506.
Ebrahimi, G., et al. Serum Versus Peripheral Blood Mononuclear Cells (PBMCs): Different MicroRNA Profiles in Sarcoidosis Patients. American Journal of Respitory and Critical Care Medicine AJRCCM (2020) Abstract B35
Buschur, K., et al. Vaping-Associated Variation in MicroRNA Expression in Circulating Extraceullular Vesicles. American Journal of Respitory and Critical Care Medicine AJRCCM (2020) Abstract A29.
Danza, J., et al. HLA-E Expression Predicts Progression, Therapeutic Response and Overall Survival in Patients with Bladder Cancer. The Journal of Urology 2020 APR: 203(4) e228-e229.
Hierro, C., et al. FGFR1-4 High mRNA Expression (mRNAh) as Predictive Biomarker for FGFR Inhibitors in Breast Cancer (BC). Annals of Oncology 2020 MAR:31(S1),S8-S9., Abstract 29P.
Garg, R., et al. Inflammatory and Genetic Signatures for Recurrent Oropharynx Cancer. International Journal of Radiation Oncology. 2020 APR 1:106(5);1173. Abstract 288
Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)
Lenz, A., et al. CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials. Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)
Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.
Dora, D., et al. Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribtution. bioRxiv preprint 2020 Feb 3. doi:https://doi.org/10.1101/2020.02.02.930305
Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.
Page last updated May 22, 2023